Drug Pricing Transparency and Accountability Act

United States118th CongressHR-198House of Representatives
Updated: Dec 17, 2024

Summary

Drug Pricing Transparency and Accountability Act This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  2. Introduced in House

  3. Referred to the Subcommittee on Health.

    House of Representatives

  4. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.